NASDAQ: WHWKWhitehawk Therapeutics Inc Stock
$1.99-0.02 (-1%)
Updated Sep 12, 2025
WHWK Price
$1.99
Fair Value Price
N/A
Market Cap
$93.75M
52 Week Low
$1.39
52 Week High
$3.81
P/E
12.44x
P/B
0.42x
P/S
2.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$27.78M
Earnings
$27.61M
Gross Margin
88.7%
Operating Margin
99.77%
Profit Margin
99.4%
Debt to Equity
0.06
Operating Cash Flow
-$52M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WHWK Overview
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WHWK's potential to beat the market
- WHWK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
WHWK
RankedUnranked of 476
RankedUnranked of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $37.96 | A | |
| $7.91 | A |
Be the first to know about important WHWK news, forecast changes, insider trades & much more!
WHWK News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WHWK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WHWK was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WHWK is good value based on its earnings relative to its share price (12.44x), compared to the US market average (36.98x)
P/E vs Market Valuation
WHWK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more WHWK due diligence checks available for Premium users.
Valuation
WHWK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.44x
Industry
-97.08x
Market
36.98x
WHWK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
WHWK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
WHWK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
4.65x
WHWK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WHWK's financial health
Profit margin
Revenue
$7.1M
Net Income
$73.0M
Profit Margin
1,021.9%
WHWK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
WHWK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$234.0M
Liabilities
$12.3M
Debt to equity
0.06
WHWK's short-term assets ($232.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WHWK's short-term assets ($232.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WHWK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WHWK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.9M
Investing
$115.5M
Financing
$95.2M
WHWK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WHWK vs Biotech Stocks
Whitehawk Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.